Prime Minister's Ventures participates in a €10 million funding of Animab, farmers' organization's business venture.
Belgian Biotech Firm Animab Therapeutics Nears Launch of Antibiotic-Free Solution for Pig Farmers
Animab Therapeutics, a Belgian biotech company, is developing a groundbreaking antibody-based product called Nanoprotec. The product is designed to combat gastrointestinal infections in pigs, offering farmers an antibiotic-free and easily scalable alternative to current medication.
The company recently secured €10 million in funding, led by PMV, the Flemish state-owned investor, AIF, QBIC, Seventure Partners, and laboratory group Anacura. Felix Van Camp, a business strategist at Anacura, expressed his enthusiasm about investing in Animab at this pivotal moment, citing the strength of Nanoprotec and Animab's promising pipeline, as well as the proven credibility of its leadership.
According to Animab, a product launch for Nanoprotec is planned for the end of 2026. However, the exact timeline for regulatory approval has not been publicly disclosed.
Typically, the commercial launch and regulatory approval for veterinary biologics like Nanoprotec depend on several factors, including the completion of preclinical and clinical trials, submission and review of data dossiers by regulatory authorities, and manufacturing scale-up and quality control processes.
Assuming Nanoprotec is in late-stage development, a typical timeline might be:
- Regulatory submission: Within 1-2 years
- Regulatory review and approval: Approximately 1-2 years after submission
- Commercial launch: Shortly after approval, possibly 3-4 years from late-stage development
To obtain the most accurate and up-to-date timeline, it is recommended to check Animab’s official announcements or press releases, monitor filings with relevant veterinary regulatory agencies, or contact Animab directly or consult industry reports.
Alain Wille, CEO of Animab, has stated that the funding will be used for the commercial launch of its oral antibody and the advancement of its broader product pipeline. Before the end of this year, Nanoprotec is set to be sent to the European Medicines Agency for regulatory submission.
Nanoprotec works by being given to piglets in their drinking water. It prevents bacterial adhesion to the intestinal wall, neutralizing potentially harmful pathogens. The European Union supports Animab under its InvestEU programme.
Stay tuned for more updates on Animab Therapeutics and the impending launch of Nanoprotec.
- Private equity firms such as PMV, AIF, QBIC, and Seventure Partners, along with laboratory group Anacura, have invested €10 million into Animab Therapeutics, a Belgian biotech company.
- The funding will be used by Animab to commercially launch its antibody-based product, Nanoprotec, and advance its broader product pipeline.
- Nanoprotec, designed to combat gastrointestinal infections in pigs, is an antibiotic-free and scalable alternative to current medication.
- The European Medicines Agency will receive Nanoprotec for regulatory submission before the end of this year.
- Assuming Nanoprotec is in late-stage development, a regulatory review and approval could take around 1-2 years after submission, with a commercial launch shortly afterward, possibly 3-4 years from late-stage development.
- With the launch of Nanoprotec, Animab is venturing into the realm of health-and-wellness, focusing on the fitness-and-exercise and medical-conditions of farm animals, while employing technology and forging ahead in data-and-cloud-computing and real-estate investments, all facilitated by finance and investing in venture capital.
